Trial Profile
Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Perflutren (Primary) ; Yttrium-90
- Indications Liver cancer
- Focus Diagnostic use; Therapeutic Use
- 29 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2023 Planned End Date changed from 29 Dec 2023 to 1 Jul 2024.
- 31 Oct 2023 Planned primary completion date changed from 12 Jul 2023 to 25 Feb 2024.